EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients

Emilie Cayssials, Lucie Lefèvre, Amandine Decroos, Florence Jacomet, Nathalie Piccirilli, Florence Tartarin, François Guilhot, Jean-Claude Chomel, Philippe Rousselot, Franck E Nicolini, Stéphanie Ragot, Jean-Marc Gombert und 3 weitere

Cancer Immunology, Immunotherapy · 19.12.2025 · 75 (1)

DOI: 10.1007/s00262-025-04256-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 19.12.2025. Verfasst von Emilie Cayssials und 14 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1313, IRMETIST, CHU Poitiers, Université de Poitiers, Poitiers, France. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, CD8-Positive T-Lymphocytes, Biomarkers, Tumor, Immunity, Innate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National Du Cancer, Association Laurette Fugain, Cancéropôle Grand Sud-Ouest.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In chronic myeloid leukemia (CML), the role of immune effectors has been suggested in the achievement of a sustained deep molecular response (DMR) and treatment-free remission (TFR) after tyrosine kinase inhibitor (TKI) discontinuation. A contributory role of the distinct new innate CD8 T-cell pool in control of CML residual disease after TKI cessation was recently highlighted. Here, we evaluated longitudinally whether innate CD8 T-cells predict CML therapy success in a cohort of newly diagnosed CML patients treated in the DASA-PegIFN clinical trial. After 3 months of treatment (M3), we observed a significant increase in innate CD8 T-cell frequency as compared to diagnosis, together with an early shift within the pool of CD8 T-cells toward an innate/memory phenotype. We also found that patients with high innate CD8 T-cell frequency at M3 achieved DMR earlier and at higher rates than patients with low innate CD8 T-cell frequency. Remarkably, this signature pre-existed at the time of diagnosis, suggesting the possible role of the patient's initial individual immune status. High innate CD8 T-cell frequency was also associated with maintaining DMR stability for 2 years. Taken together, our findings highlight innate CD8 T-cells as a potential marker for CML therapy success and TFR eligibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveCD8-Positive T-LymphocytesBiomarkers, TumorImmunity, InnateHumansMaleFemaleMiddle AgedAdultProtein Kinase InhibitorsAgedTreatment OutcomePrognosis

Stichwörter der Autor:innen

Chronic myeloid leukemiaDeep molecular responseImmune biomarkerInnate CD8 T-cell

Substanzen

Protein Kinase InhibitorsBiomarkers, Tumor

Autor:innen und Institutionen

  • INSERM U1313, IRMETIST, CHU Poitiers, Université de Poitiers, Poitiers, France.
  • Service d'Oncologie Hématologique et Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.
  • Fi-LMC, Centre Léon Bérard, Lyon, France.
  • INSERM CIC-1402, Poitiers, France.
  • Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France.
  • Service de Cancérologie Biologique, CHU de Poitiers, Poitiers, France.

Förderung

  • Institut National Du Cancer
  • Association Laurette Fugain
  • Cancéropôle Grand Sud-Ouest
  • Ligue contre le Cancer du Grand Ouest
  • Association Sport et Collection
  • France intergroupe des Leucemies Myéloides Chroniques
  • Association pour la Recherche en Immunologie-Poitou-Charentes
  • Conseil Régional Aquitaine

Zitieren

APA

Cayssials, E., Lefèvre, L., Decroos, A., Jacomet, F., Piccirilli, N., Tartarin, F., Guilhot, F., Chomel, J. C., Rousselot, P., Nicolini, F. E., Ragot, S., Gombert, J. M., Roy, L., Herbelin, A., & Barbarin, A. (2025). Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients. Cancer Immunology, Immunotherapy, 75(1). https://doi.org/10.1007/s00262-025-04256-0

Vancouver

Cayssials E, Lefèvre L, Decroos A, Jacomet F, Piccirilli N, Tartarin F, et al. Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients. Cancer Immunology, Immunotherapy. 2025;75(1). doi:10.1007/s00262-025-04256-0

BibTeX
@article{Cayssials2025,
  author = {Cayssials, Emilie and Lefèvre, Lucie and Decroos, Amandine and Jacomet, Florence and Piccirilli, Nathalie and Tartarin, Florence and Guilhot, François and Chomel, Jean-Claude and Rousselot, Philippe and Nicolini, Franck E and Ragot, Stéphanie and Gombert, Jean-Marc and Roy, Lydia and Herbelin, André and Barbarin, Alice},
  title = {Innate CD8 T-cells as a potential predictive biomarker for deep molecular response in chronic myeloid leukemia patients},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  volume = {75},
  number = {1},
  doi = {10.1007/s00262-025-04256-0}
}
Kostenlos starten →